Ownership and insider activity for FibroBiologics, Inc. Common Stock (FBLG): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
Price
| Price | $1.43 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Khoja Hamid | A-Award | 298,508 | $500K |
| 2026-09-15 | Khoja Hamid | A-Award | 298,508 | $463K |
| 2026-08-20 | Steinberg Leigh | |||
| 2026-07-08 | Rubins Kathleen Hallisey | 562 | $37K | |
| 2026-06-23 | Hoffman Robert E. | A-Award | 30,803 | $23K |
| 2026-06-23 | Cilento Richard C. Jr. | A-Award | 30,803 | $23K |
| 2026-06-23 | Link Matthew | A-Award | 30,803 | $23K |
| 2026-06-23 | Niklas Victoria Ninon Olivia | A-Award | 30,803 | $23K |
| 2026-05-04 | O'HEERON PETE | A-Award | 92,410 | $128K |
| 2026-05-04 | Khoja Hamid | A-Award | 61,607 | $85K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $407000 | $2.3M | $9.2M | $14.0M | $4.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $300000 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | $468000 | $2.6M | $9.2M | $14.2M | $6.3M |
| Property, Plant & Equipment | 0 | 0 | $2.2M | $2.6M | $2.2M | $3.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0 | $468000 | $4.8M | $11.8M | $16.4M | $9.6M |
| Accounts Payable | 0 | $233000 | $758000 | $1.4M | $2.7M | $945000 |
| Short-term Debt | 0 | $1.3M | $5.5M | 0 | $9.2M | 0 |
| Total Current Liabilities | 0 | $1.8M | $7.1M | $9.2M | $12.7M | $1.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0 | $1.8M | $8.8M | $10.6M | $13.7M | $3.5M |
| Retained Earnings | -$1.2M | -$2.8M | -$7.9M | -$24.4M | -$35.5M | -$54.2M |
| Total Equity | 0 | -$1.3M | -$4.0M | $1.3M | $2.7M | $6.2M |
| Total Debt | 0 | $1.3M | $7.5M | $1.7M | $10.6M | $2.4M |
| Net Debt | 0 | $893000 | $5.3M | -$7.4M | -$3.4M | -$2.5M |
| Working Capital | 0 | -$1.3M | -$4.4M | $32000 | $1.5M | $4.6M |
Financial Health
| Debt / Equity | 0.32 |
| Current Ratio | 2.64 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -11.28 |
Profitability
| Return on Equity | -536.78% |
| Return on Invested Capital | -274.34% |
| Return on Assets | -228.77% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADTX · AIMD · APLM · ATHA · CTXR · DARE · HOTH
Explore sector: Healthcare · Biotechnology
More sections of FBLG: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks